S&P 500   4,555.32 (-0.43%)
DOW   35,522.54 (-0.66%)
QQQ   381.31 (+0.58%)
AAPL   149.15 (-0.11%)
MSFT   324.31 (+4.58%)
FB   313.61 (-0.70%)
GOOGL   2,939.06 (+5.49%)
TSLA   1,036.40 (+1.76%)
AMZN   3,403.73 (+0.82%)
NVDA   245.90 (-0.51%)
BABA   169.28 (-0.42%)
NIO   39.40 (-2.64%)
CGC   12.86 (-2.35%)
GE   104.18 (-3.03%)
AMD   122.74 (-0.15%)
MU   68.52 (-0.61%)
T   25.08 (-1.14%)
F   15.59 (-2.20%)
ACB   6.81 (-3.13%)
DIS   169.91 (-1.24%)
PFE   42.99 (-1.31%)
BA   207.64 (-1.03%)
AMC   34.86 (-3.30%)
S&P 500   4,555.32 (-0.43%)
DOW   35,522.54 (-0.66%)
QQQ   381.31 (+0.58%)
AAPL   149.15 (-0.11%)
MSFT   324.31 (+4.58%)
FB   313.61 (-0.70%)
GOOGL   2,939.06 (+5.49%)
TSLA   1,036.40 (+1.76%)
AMZN   3,403.73 (+0.82%)
NVDA   245.90 (-0.51%)
BABA   169.28 (-0.42%)
NIO   39.40 (-2.64%)
CGC   12.86 (-2.35%)
GE   104.18 (-3.03%)
AMD   122.74 (-0.15%)
MU   68.52 (-0.61%)
T   25.08 (-1.14%)
F   15.59 (-2.20%)
ACB   6.81 (-3.13%)
DIS   169.91 (-1.24%)
PFE   42.99 (-1.31%)
BA   207.64 (-1.03%)
AMC   34.86 (-3.30%)
S&P 500   4,555.32 (-0.43%)
DOW   35,522.54 (-0.66%)
QQQ   381.31 (+0.58%)
AAPL   149.15 (-0.11%)
MSFT   324.31 (+4.58%)
FB   313.61 (-0.70%)
GOOGL   2,939.06 (+5.49%)
TSLA   1,036.40 (+1.76%)
AMZN   3,403.73 (+0.82%)
NVDA   245.90 (-0.51%)
BABA   169.28 (-0.42%)
NIO   39.40 (-2.64%)
CGC   12.86 (-2.35%)
GE   104.18 (-3.03%)
AMD   122.74 (-0.15%)
MU   68.52 (-0.61%)
T   25.08 (-1.14%)
F   15.59 (-2.20%)
ACB   6.81 (-3.13%)
DIS   169.91 (-1.24%)
PFE   42.99 (-1.31%)
BA   207.64 (-1.03%)
AMC   34.86 (-3.30%)
S&P 500   4,555.32 (-0.43%)
DOW   35,522.54 (-0.66%)
QQQ   381.31 (+0.58%)
AAPL   149.15 (-0.11%)
MSFT   324.31 (+4.58%)
FB   313.61 (-0.70%)
GOOGL   2,939.06 (+5.49%)
TSLA   1,036.40 (+1.76%)
AMZN   3,403.73 (+0.82%)
NVDA   245.90 (-0.51%)
BABA   169.28 (-0.42%)
NIO   39.40 (-2.64%)
CGC   12.86 (-2.35%)
GE   104.18 (-3.03%)
AMD   122.74 (-0.15%)
MU   68.52 (-0.61%)
T   25.08 (-1.14%)
F   15.59 (-2.20%)
ACB   6.81 (-3.13%)
DIS   169.91 (-1.24%)
PFE   42.99 (-1.31%)
BA   207.64 (-1.03%)
AMC   34.86 (-3.30%)
NASDAQ:VTGN

VistaGen Therapeutics Stock Forecast, Price & News

$2.24
-0.06 (-2.61 %)
(As of 10/27/2021 03:40 PM ET)
Add
Compare
Today's Range
$2.16
▼
$2.30
50-Day Range
$2.30
▼
$3.17
52-Week Range
$0.61
▼
$3.55
Volume
55,040 shs
Average Volume
2.45 million shs
Market Capitalization
$432.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.92
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


VistaGen Therapeutics logo

About VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Headlines

One VistaGen Therapeutics, Inc. (NASDAQ:VTGN) insider reduced their stake by 29% in the previous year
October 27, 2021 |  nasdaq.com
$330,000.00 in Sales Expected for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) This Quarter
October 27, 2021 |  americanbankingnews.com
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expected to Announce Quarterly Sales of $330,000.00
October 27, 2021 |  americanbankingnews.com
Analysts Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to Post -$0.05 EPS
October 25, 2021 |  americanbankingnews.com
-$0.05 Earnings Per Share Expected for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) This Quarter
October 25, 2021 |  americanbankingnews.com
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Update
October 18, 2021 |  americanbankingnews.com
VistaGen Therapeutics (NASDAQ:VTGN) Receives New Coverage from Analysts at Robert W. Baird
October 17, 2021 |  americanbankingnews.com
VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
October 14, 2021 |  markets.businessinsider.com
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
October 14, 2021 |  finance.yahoo.com
Analysts Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $330,000.00
October 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTGN
Previous Symbol
CUSIP
N/A
CIK
1411685
Web
www.vistagen.com
Phone
(650) 577-3600
Employees
21
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.09 million
Price / Sales
396.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
4.39

Profitability

EPS (Most Recent Fiscal Year)
($0.49)
Net Income
$-17.93 million
Net Margins
-1,561.84%
Return on Equity
-32.73%
Return on Assets
-26.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.93
Quick Ratio
15.93

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
192,904,000
Market Cap
$432.10 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

2.35 out of 5 stars

Medical Sector

222nd out of 1,365 stocks

Pharmaceutical Preparations Industry

97th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

Is VistaGen Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than VistaGen Therapeutics?

Wall Street analysts have given VistaGen Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VistaGen Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VistaGen Therapeutics?

VistaGen Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 12,080,000 shares, an increase of 29.5% from the September 15th total of 9,330,000 shares. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is presently 11.1 days. Currently, 8.3% of the company's shares are short sold.
View VistaGen Therapeutics' Short Interest.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for VistaGen Therapeutics.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Thursday, August, 12th. The company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.01. The company had revenue of $0.35 million for the quarter, compared to analysts' expectations of $0.37 million. VistaGen Therapeutics had a negative net margin of 1,561.84% and a negative trailing twelve-month return on equity of 32.73%.
View VistaGen Therapeutics' earnings history.

How has VistaGen Therapeutics' stock been impacted by Coronavirus?

VistaGen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VTGN shares have increased by 338.0% and is now trading at $2.19.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VTGN?

3 Wall Street analysts have issued 1-year price targets for VistaGen Therapeutics' stock. Their forecasts range from $5.00 to $9.00. On average, they expect VistaGen Therapeutics' share price to reach $6.67 in the next year. This suggests a possible upside of 204.4% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics or view top-rated stocks among Wall Street analysts.

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:
  • Shawn K. Singh, Chief Executive Officer & Director
  • H. Ralph Snodgrass, President & Chief Scientific Officer
  • Jerrold D. Dotson, Chief Financial Officer, Secretary & VP
  • Mark A. Smith, Chief Medical Officer
  • Ellis Wilson, Vice President-Global Clinical Operations

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Epiq Partners LLC (0.47%) and Genesee Capital Advisors LLC (0.01%). Company insiders that own VistaGen Therapeutics stock include H Ralph Snodgrass and Jerrold Duane Dotson.
View institutional ownership trends for VistaGen Therapeutics.

Which institutional investors are selling VistaGen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including Epiq Partners LLC.
View insider buying and selling activity for VistaGen Therapeutics or view top insider-selling stocks.

Which institutional investors are buying VistaGen Therapeutics stock?

VTGN stock was bought by a variety of institutional investors in the last quarter, including Genesee Capital Advisors LLC.
View insider buying and selling activity for VistaGen Therapeutics or or view top insider-buying stocks.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $2.19.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics has a market capitalization of $422.46 million and generates $1.09 million in revenue each year. The company earns $-17.93 million in net income (profit) each year or ($0.49) on an earnings per share basis.

How many employees does VistaGen Therapeutics have?

VistaGen Therapeutics employs 21 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

Where are VistaGen Therapeutics' headquarters?

VistaGen Therapeutics is headquartered at 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 577-3600 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.